Litigation Details for Genentech, Inc. v. Amgen Inc. (D. Del. 2017)

« Back to Dashboard

Genentech, Inc. v. Amgen Inc. (D. Del. 2017)

Docket		Date Filed	2017-10-06
Court	District Court, D. Delaware	Date Terminated	2020-07-07
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To	Sherry R. Fallon
Parties	AMGEN INC.
Patents	8,460,895; 8,512,983; 8,574,869; 9,441,035; 9,487,809; 9,714,293
Attorneys	Benjamin A. Smyth
Firms	Proskauer Rose LLP
Link to Docket	External link to docket

Biologic Drugs cited in Genentech, Inc. v. Amgen Inc.

Details for Genentech, Inc. v. Amgen Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-10-06				External link to document

Litigation summary and analysis for: Genentech, Inc. v. Amgen Inc. (D. Del. 2017)

Last updated: August 1, 2026

Genentech v. Amgen (1:17-cv-01407) Litigation Summary and Analysis: What Patent Disputes Were Actually Tried, Who Won What, and What It Means for Biosimilar Risk

Genentech, Inc. and Amgen litigated patent claims in U.S. District Court for the District of Delaware under case number 1:17-cv-01407, with the dispute centered on biosimilar-adjacent intellectual property tied to a Genentech biologic and Amgen’s related product program. The docket reflects a complex lifecycle that includes pleadings, claim construction and pretrial motion practice typical of Delaware Hatch-Waxman-style patent disputes adapted for biologics, then resolution through a combination of court rulings and/or case disposition consistent with settlement or final judgment mechanics.

Result to investors and biosimilar strategists: the litigation posture and outcome functionally shaped market-entry timing and design-around feasibility, and the residual IP risk depends on which asserted claims were narrowed versus which remained enforceable post-ruling.

---

What was Genentech v. Amgen 1:17-cv-01407 about? (core dispute, parties, and asserted rights)

Case: Genentech, Inc. v. Amgen Inc.
Court: U.S. District Court for the District of Delaware
Case number: 1:17-cv-01407
Parties:

• Plaintiff: Genentech, Inc.
• Defendant: Amgen Inc.

Core issue: the case is a patent enforcement action tied to a biologics/patent estate dispute where Genentech alleged that Amgen’s planned or licensed biologic would infringe one or more claims covering the patented subject matter associated with Genentech’s product.

What the case structurally implies (based on the Delaware biosimilar litigation pattern):

• Asserted patents typically fall into at least one of these buckets:
  • molecule/composition claims
  • manufacturing/process claims
  • formulation and/or delivery claims
  • method-of-use or therapeutic claims
• The pretrial phase in Delaware commonly includes claim construction, infringement and validity briefing, and often preliminary injunction-related posture even if ultimate disposition occurs later.

---

Which patents were asserted in 1:17-cv-01407 and how did Genentech frame infringement?

Available docket-level and publication-level details for this specific case are not provided in the input. Without the asserted patent numbers (and their claim sets), it is not possible to produce an accurate, claim-by-claim infringement/validity analysis.

What matters for analysis nonetheless:

• In Delaware bench adjudication or jury-trial posture varies, but outcomes generally hinge on:
  • whether Amgen’s product met each claim limitation (literal or doctrine of equivalents)
  • whether asserted patents survived validity challenges (anticipation, obviousness, written description/enablement, indefiniteness)

---

What happened procedurally in Genentech v. Amgen 1:17-cv-01407 (motions, claim construction, trial posture, and resolution mechanics)?

In Delaware patent cases at this posture, the case timeline typically includes these decision points:

1. Pleadings and early motions

   • Rule 12 motions, answers, and scheduling
   • Joinder of experts and infringement/validity frameworks

2. Claim construction

   • The court interprets claim terms, constraining both infringement and invalidity arguments
   • Narrow constructions often reduce infringement exposure or increase invalidity likelihood

3. Summary judgment and dispositive rulings

   • Parties seek partial summary judgment on key issues
   • Courts may narrow the case to fewer asserted claims

4. Final disposition

   • Resolution occurs via:
     • final judgment after trial, or
     • case dismissal following settlement, consent judgment, or covenant outcomes
   • Even where a “win” is reported, practitioners track which claims survived and whether design-around remained feasible.

Impact framing: if claim construction narrowed key elements, Amgen’s noninfringement or invalidity position usually improves. If the court held claims broad and valid, then licensing or redesign becomes more expensive.

---

Who won Genentech v. Amgen 1:17-cv-01407 and what did the court actually decide?

Outcome-specific holdings are not present in the provided input. Without the actual judgment entry text and dates, any “who won” statement would be speculative and would not meet an actionable litigation summary standard.

What you can reliably infer from settlement-prone Delaware biosimilar disputes: many such cases end with either:

• entry of a judgment after a final merits ruling on at least some claims, or
• dismissal/stipulation tied to settlement terms governing launch timing and/or royalty structure.

---

How did patent strength in 1:17-cv-01407 affect settlement and future biosimilar risk?

Patent strength in these cases is measured less by “asserted patents exist” and more by whether the court:

• construes claims narrowly,
• rejects obviousness/anticipation,
• allows a valid “design-around” to remain credible.

If claims were weakened:

• Amgen’s risk profile improves.
• Future FDA filing and launch timing face less IP friction.
• Licensing pressure shifts to narrower claim sets.

If claims were upheld:

• Launch timing becomes more constrained.
• The market participant either pays licensing terms or delays entry.
• Competitors face increased uncertainty on manufacturing/process or sequence fidelity if composition/process claims remain enforceable.

---

What commercial and regulatory timelines could be impacted by 1:17-cv-01407?

Even without the specific asserted patents, the commercial linkage in biosimilar litigation typically flows through:

• anticipated launch eligibility
• manufacturing scale-up
• contractual pricing and distribution readiness

If the litigation outcome enforces an injunction or blocks entry until patent expiry, the affected window is measured against:

• the remaining term of asserted patents
• any granted exclusivities tied to the biologic’s regulatory status
• any court-ordered stay or sunset date.

However, no patent expiration dates or regulatory milestones for this case are included in the input. A timeline with hard dates cannot be generated.

---

What is the Orange Book status impact for this dispute (and why it may matter even for biologics)?

For biologics, exclusivity and listing mechanics differ from the Orange Book for small molecules. Yet investors still track Orange Book-adjacent concepts:

• whether there is a corresponding small-molecule listing
• whether the asserted claims correlate with listed reference-product patents

No Orange Book listing identifiers or FDA reference product details are provided in the input, so a status analysis cannot be stated as fact.

---

Did this case involve Paragraph IV-style challenges or biosimilar-specific defenses?

The dispute caption alone does not determine whether this is:

• a biosimilar patent infringement case under the biologics regime,
• an ANDA-style Paragraph IV matter adapted for biologics,
• or an overlap with Hatch-Waxman for a related product.

Because the input does not include the asserted patent listing mechanism (or the FDA pathway), an accurate procedural categorization cannot be produced.

---

How does Genentech v. Amgen 1:17-cv-01407 compare with other Genentech–Amgen patent battles?

Amgen and Genentech have had multiple IP confrontations across biologics and method/process claims in other matters. The most consistent comparative metric is whether courts tend to:

• invalidate key claims,
• uphold them and push settlement,
• or narrow scope through claim construction.

A cross-case comparison for this specific case requires docket-specific findings, asserted patents, and ruling outcomes that are not included in the input.

---

Key Takeaways

• Case: Genentech, Inc. v. Amgen Inc., 1:17-cv-01407 in Delaware.
• Dispute type: a patent infringement litigation with biosimilar-adjacent commercial impact typical of Genentech–Amgen disputes.
• Actionability: the litigation meaning for market entry hinges on which asserted claims survived claim construction and dispositive rulings, and on whether the docket ends in final judgment or settlement-driven dismissal.
• Missing from the provided input: asserted patent numbers, court holdings, and dates. Without those, any “which patents won” or “expiration timeline” analysis would not be precise.

---

FAQs

1. What is the court’s role in biosimilar patent claim construction in Delaware cases like 1:17-cv-01407?
2. How do settlement dismissals typically differ from final merits judgments in Genentech–Amgen litigation?
3. What claim types (composition, manufacturing, method-of-use) most often drive noninfringement in biologic cases?
4. How do injunction or denial outcomes translate into practical launch timing for biosimilar sponsors?
5. What documentation do litigators track on the docket to assess residual IP risk after dismissal?

---

References (APA)

No sources were provided or cited in the input.